A lawsuit has been filed claiming that the use of Dupixent led to a diagnosis of cutaneous T-cell lymphoma (CTCL), with enlarged lymph nodes being a factor in the diagnosis. The lawsuit also mentions other specific types of T-cell lymphoma, including peripheral T-cell lymphoma, mycosis fungoides, and Sezary syndrome. Reports indicate that the diagnosis resulted in significant medical treatment, including multiple rounds of chemotherapy.